Insulet (NASDAQ:PODD) Price Target Cut to $340.00 by Analysts at JPMorgan Chase & Co.

Insulet (NASDAQ:PODD) had its price objective dropped by JPMorgan Chase & Co. from $415.00 to $340.00 in a report issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 39.57% from the stock’s previous close.

A number of other research firms also recently issued reports on PODD. The Goldman Sachs Group restated a “buy” rating and set a $326.00 price objective on shares of Insulet in a report on Thursday. Sanford C. Bernstein set a $330.00 price target on shares of Insulet in a report on Thursday. Jefferies Financial Group increased their price objective on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, November 6th. UBS Group restated a “buy” rating on shares of Insulet in a research note on Thursday, December 18th. Finally, Barclays restated an “underweight” rating and issued a $286.00 target price on shares of Insulet in a research note on Thursday. Twenty investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $359.10.

Insulet Stock Down 5.6%

Shares of PODD stock traded down $14.46 on Thursday, reaching $243.61. 297,566 shares of the company were exchanged, compared to its average volume of 969,056. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The company has a 50-day moving average of $274.42 and a 200-day moving average of $305.50. The company has a market cap of $17.14 billion, a price-to-earnings ratio of 70.63, a PEG ratio of 1.39 and a beta of 1.41. Insulet has a one year low of $230.05 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. The firm had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.15 earnings per share. Analysts anticipate that Insulet will post 3.92 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC boosted its holdings in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. purchased a new stake in Insulet in the fourth quarter worth about $26,000. True Wealth Design LLC lifted its position in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares in the last quarter. DV Equities LLC purchased a new stake in Insulet in the 4th quarter worth approximately $28,000. Finally, Elyxium Wealth LLC bought a new stake in Insulet during the fourth quarter valued at about $28,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q4 results beat and margin expansion: Insulet reported $1.55 EPS vs. ~$1.48 expected and revenue of $783.8M (+31% YoY), with improving margins — a core reason for recent investor enthusiasm. Insulet beats quarterly estimates on strong demand for wearable insulin pumps
• Positive Sentiment: Share repurchase expanded: Management boosted the buyback program, which reduces float and signals confidence from the company. Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
• Positive Sentiment: Product/market momentum: Omnipod unit growth, expansion into type‑2 diabetes and ongoing innovation are cited as drivers of outperformance and the company’s multi‑year growth runway. PODD Q4 deep dive: Type 2 diabetes expansion and innovation drive outperformance
• Neutral Sentiment: Analyst actions mixed but still bullish: Firms reiterated buy/outperform stances (BTIG kept a $380 target) even as some targets were trimmed (Leerink cut its target to $360 while keeping an outperform). That is supportive long term but can add short‑term volatility. Benzinga – analyst notes BTIG Reiterates Buy on Insulet
• Negative Sentiment: Near‑term guidance/quarter sequencing concerns: although FY‑2026 revenue guidance was upbeat, some commentary and Q1 revenue/near‑term signals were viewed as conservative versus Street expectations — a common catalyst for profit‑taking after a strong run. Insulet beats quarterly estimates on strong demand for wearable insulin pumps

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.